Datascope acquired Artema Medical AB, continuing our expansion of
product offerings in the anesthesia monitoring market. Artema's revenue
grew 35% last year and we are confident Artema's products will drive
top-line growth, improve operating margins and be accretive to earnings
in fiscal 2008.
DATASCOPE HAS THE RIGHT BOARD OF DIRECTORS IN PLACE --
INDEPENDENT, EXPERIENCED AND FOCUSED ON CREATING VALUE
Under the leadership of your Board and senior management, Datascope has enjoyed 35 years of consistent profitability. We have a strong balance sheet, with no debt, robust cash generation, and a healthy new product pipeline which, along with our strengthened management, solidly positions Datascope for sustainable and profitable growth.
A majority of Datascope's seven-member Board is independent. Your directors bring the necessary depth and breadth of expertise in areas that are critical to Datascope's continued success. Your Board's interests are closely aligned with those of all Datascope shareholders. No one has more at stake in Datascope than founder and CEO, Lawrence Saper, who owns almost 16% of the Company's common stock.
Each of your directors standing for re-election at this year's Annual Meeting -- James Loughlin and William Asmundson -- occupies an important leadership position and brings considerable experience and knowledge to your Board:
- James Loughlin serves as chairperson of the Audit Committee, is a
financial expert as defined under Securities and Exchange Commission
(SEC) rules, and is a member of the Compensation Committee. Mr. Loughlin
is a retired senior partner of one of the world's major accounting firms
and led its Life Science and Pharmaceuticals practices.
- William Asmundson serves as the lead outside director and presides over
executive sessions and meetings
|SOURCE Datascope Corp.|
Copyright©2007 PR Newswire.
All rights reserved